All Stories

  1. Direct Oral Anticoagulants, COX-2–Selective NSAIDs, and Gastrointestinal Bleeding in Atrial Fibrillation
  2. Re‐evaluation of sucralose (E 955) as a food additive and evaluation of a new application on extension of use of sucralose (E 955) in fine bakery wares
  3. Influenza Immunization at Midlife and the Risk of Parkinson Disease
  4. Use of fluoroquinolones and the risk of seizures: a population-based cohort study
  5. Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study
  6. A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis
  7. Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study
  8. Concomitant use of direct oral anticoagulants and interacting antiarrhythmic drugs and the risk of stroke and bleeding among patients with non-valvular atrial fibrillation: a multinational cohort study
  9. Serum uric acid and the risk of major adverse cardiovascular events and death among older adults: a population-based prospective cohort study
  10. Invited Commentary: Building rigorous clinical evidence for drug-drug interactions
  11. Ibuprofen gegen alles?
  12. Effectiveness and safety of concomitant use of direct oral anticoagulants and antiarrhythmic drugs: a systematic review of observational studies
  13. The Risk of Bleeding in Pregnant Women with Acute Venous Thromboembolism Treated with Anticoagulants: An International Multi-Database Cohort Study
  14. Advancing Health Equity in Europe: Explore, Tailor, Implement, and Evaluate (ETIE)—A Framework of Diversity and Fairness in Pharmacoepidemiologic Research
  15. CTRH as Biomarker of Drug Efficacy: In-Depth Assessment of Real-World Evidence
  16. Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies
  17. Evaluation of Drug–Drug Interactions in Pharmacoepidemiologic Research
  18. Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events
  19. Handbook of Epidemiology
  20. The Prevalent New‐User Design to Study Drug–Drug Interactions: The Example of Sulfonylureas and Warfarin Interaction on the Risk of Severe Hypoglycemia
  21. Comparative risk of infection of medications used for type 2 diabetes
  22. Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events
  23. Opioid Use and the Risk of Ventricular Arrhythmias: A Systematic Review and Meta‐Analysis
  24. Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis
  25. Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population‐based cohort study
  26. Methodological Considerations on the Use of Cohort Designs in Drug-Drug Interaction Studies in Pharmacoepidemiology
  27. Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study
  28. Infectious Disease Burden and the Risk of Alzheimer’s Disease: A Population-Based Study
  29. Diagnostic Validity of Chronic Kidney Disease in Health Claims Data Over Time: Results from a Cohort of Community-Dwelling Older Adults in Germany
  30. Clinically apparent Helicobacter pylori infection and the risk of incident Alzheimer's disease: A population‐based nested case‐control study
  31. Incretin‐based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta‐analysis of observational studies
  32. Kidney function estimators for drug dose adjustment of direct oral anticoagulants in older adults with atrial fibrillation
  33. Pharmacologic heterogeneity and risk of severe hypoglycemia with concomitant use of sulfonylureas and DPP‐4 inhibitors: population‐based cohort study
  34. Kidney Measures and Risk of Incident Heart Failure Among Older Adults
  35. Considerations on the use of different comparators in pharmacovigilance: a methodological review
  36. Use of a Statistical Adaptive Treatment Strategy Approach for Emulating Randomized Controlled Trials Using Observational Data: The Example of Blood Pressure Control Strategies for the Prevention of Cardiovascular Events Among Individuals with Hypertens...
  37. Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting ‐ A disproportionality analysis
  38. Sulfonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: a population‐based cohort study
  39. Adherence and Quality of Life in Non-Valvular Atrial Fibrillation With Direct Oral Anticoagulants Versus Vitamin K Antagonists: A Systematic Review
  40. Common vaccines and the risk of incident dementia: a population-based cohort study
  41. Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
  42. Challenges in evaluating treatments for COVID-19: The case of in-hospital anticoagulant use and the risk of adverse outcomes
  43. Effectiveness and safety of direct oral anticoagulants among octogenarians with venous thromboembolism: an international multi-database cohort study
  44. Obesity as a modifier of the Cardiovascular effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes
  45. Concomitant Use of Sulfonylureas and Warfarin and the Risk of Severe Hypoglycemia: Population-Based Cohort Study
  46. Bleeding in women with venous thromboembolism during pregnancy: A systematic review of the literature
  47. Response to: Real‐World Data on the Risk of Ventricular Arrhythmias with Sulfonamides
  48. Investigating Potential Drug-Drug Interactions from Greek e-Prescription Data
  49. Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials
  50. 5‐Alpha Reductase Inhibitors and the Risk of Anemia among Men with Benign Prostatic Hyperplasia: A Population‐based Cohort Study
  51. Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies
  52. Effectiveness and safety of direct oral anticoagulants with antiplatelet agents in patients with venous thromboembolism: A multi‐database cohort study
  53. Pharmacoepidemiology
  54. Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention among Patients with Hypertension in the United Kingdom
  55. Utilization and long‐term persistence of direct oral anticoagulants among patients with non‐valvular atrial fibrillation and liver disease
  56. Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study
  57. The Modifying Effects of Adiposity on the Cardiovascular Safety of Sulfonylureas
  58. Infectious Disease Burden and the Risk of Alzheimer’s Disease: A Population-Based Study
  59. Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence
  60. Global COVID ‐19 Pandemic and Reporting Behavior ‐ An Analysis of the Food and Drug Administration Adverse Events Reporting System ( FAERS )
  61. Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism
  62. Domperidone and the Risks of Sudden Cardiac Death and Ventricular Arrhythmia: A Systematic Review and Meta‐Analysis of Observational Studies
  63. Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis
  64. Control of blood pressure in older patients with heart failure and the risk of mortality: a population-based prospective cohort study
  65. Sodium-glucose co-transporter 2 inhibitors and the risk of venous thromboembolism in patients with type 2 diabetes: a cohort study
  66. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
  67. Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study
  68. Author response: Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study
  69. Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
  70. Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study
  71. Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis
  72. Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study
  73. Comparative cardiovascular and hypoglycemic safety of glimepiride in type 2 diabetes: A population‐based cohort study
  74. Degree of serotonin reuptake inhibition of antidepressants and ischemic risk
  75. Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes
  76. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Adverse Cardiovascular Events: A Population‐based Cohort Study
  77. Opioids and the Risk of Infection: A Critical Appraisal of the Pharmacologic and Clinical Evidence
  78. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes
  79. Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies
  80. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer
  81. RE: Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication
  82. Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study
  83. What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®
  84. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
  85. Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation
  86. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy
  87. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
  88. Use of dipeptidyl peptidase-4 inhibitors and new-onset rheumatoid arthritis in patients with type 2 diabetes
  89. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
  90. Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review
  91. Non–Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury
  92. Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study
  93. Drug-induced kidney injury: A large case series from the Berlin Case-Control Surveillance Study

  94. Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study
  95. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
  96. Immobilization and high platelet count are associated with thromboembolic complications in heparin-induced thrombocytopenia
  97. Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System
  98. Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions
  99. Pharmakovigilanz in Deutschland
  100. Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study
  101. Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones
  102. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study
  103. Estimating kidney function and use of oral antidiabetic drugs in elderly
  104. Safety issues and drug–drug interactions with commonly used quinolones
  105. Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome
  106. Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database
  107. Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases
  108. Ramipril-Induced Liver Injury: Case Report and Review of the Literature